ProCE Banner Activity

Radotinib vs Imatinib as Frontline Therapy for Newly Diagnosed Chronic-Phase CML

Slideset Download
Conference Coverage
In this phase III trial, radotinib associated with higher molecular response and lower treatment failure vs imatinib.

Released: December 11, 2015

Expiration: December 09, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen